Literature DB >> 8843626

Immunization against diphtheria with special emphasis on immunization of adults.

A M Galazka1, S E Robertson.   

Abstract

A massive diphtheria epidemic in Eastern Europe has resulted in increased anxiety that this disease could spread to other countries. This fear is realistic because there is a gap in the diphtheria immunity in large segments of the adult population in many industrialized countries. Experience to date suggests that an immunity gap in adults coupled with the presence of large numbers of susceptible children and adolescents creates the potential for an extensive epidemic. To prevent epidemics, countries should consider the immunogenicity and duration of protection provided by diphtheria toxoid given to children in the primary series and as booster doses. This paper reviews general issues related to the formulation of diphtheria immunization strategies, especially the need for booster doses in adults and the rationale for use of lower-strength diphtheria toxoid for persons older than 6 years of age.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843626     DOI: 10.1016/0264-410x(96)00021-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Response to diphtheria booster vaccination in healthy adults: vaccine trial.

Authors:  A Vellinga; P Van Damme; E Joossens; H Goossens
Journal:  BMJ       Date:  2000-01-22

2.  Use of amplified fragment length polymorphisms for typing Corynebacterium diphtheriae.

Authors:  A De Zoysa; A Efstratiou
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

3.  Immunity to diphtheria in a sample of the Canadian adult population.

Authors:  L Pelletier; P Duclos; P Gill; A Deforest
Journal:  Can J Infect Dis       Date:  1998-11

4.  Technical and diagnostic performance of five commercial anti-diphtheria toxoid IgG enzyme-linked immunosorbent assay kits.

Authors:  A Faruq; L Dadson; H Cox; F Alcock; A R Parker
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

5.  Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.

Authors:  Paul Stickings; Marisa Peyre; Laura Coombes; Sylviane Muller; Rino Rappuoli; Giuseppe Del Giudice; Charalambos D Partidos; Dorothea Sesardic
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

6.  Diphtheria immunity in Flanders.

Authors:  C Matheï; P Van Damme; P Bruynseels; H Goossens; R Vranckx; A Meheus
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

7.  Comparison of seven commercial enzyme-linked immunosorbent assays for the detection of anti-diphtheria toxin antibodies.

Authors:  A A Zasada; W Rastawicki; K Śmietańska; N Rokosz; M Jagielski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-26       Impact factor: 3.267

8.  Immune status against diphtheria among immigrants from the former USSR who arrived in Israel during 1990-1991.

Authors:  M Low; R Almog; M S Green; S Ashkenazi; H Bercovier; E Katzenelson; I Ashkenazi; J Shemer; D Cohen
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

9.  Epidemiology of epidemic diphtheria in three regions, Russia, 1994-1996.

Authors:  C R Vitek; S P Brisgalov; V Y Bragina; A M Zhilyakov; K M Bisgard; M Brennan; O N Kravtsova; B D Lushniak; R Lyerla; S S Markina; P M Strebel
Journal:  Eur J Epidemiol       Date:  1999-01       Impact factor: 8.082

10.  The recombinant protein combined vaccine based on the fragment C of tetanus toxin and the cross-reacting material 197.

Authors:  Pengdi Chai; Xiuying Pu; Jun Ge; Sulin Ren; Xiaoyu Xia; Amiao Luo; Shiwei Wang; Xiaodong Wang; Jianqiang Li
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-29       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.